

## 510(k) SUMMARY FluoroScan Profile Imaging System

Submitter Name:

FluoroScan Imaging Systems, Inc.

**Submitter Address:** 

650-B Anthony Trail Northbrook, IL 60062

Contact Person:

William J. Engel, Manager Regulatory Affairs

Phone Number:

(847) 564-5400

Fax Number:

(847) 564-5647

Date Prepared:

September 22, 2000

**Device Trade Name:** 

FluoroScan Profile

**Device Common Name:** 

Radiographic/Fluoroscopic Imaging System

Classification Name:

Mobile X-ray System

**Predicate Devices:** 

Wuestic C-Quest 4R OEC/GE Compact 7700 Philips BV300 Series Seimens Siremobil

**Device Description:** 

The Profile C-arm System is a mobile C-arm specifically designed for

X-ray imaging.

Intended Use:

The FluoroScan Profile System is designed to provide physicians with fluoroscopic and spot exposures for visualization of a patient including, but

not limited to, general surgical procedures, orthopedic, critical and emergency care, limited interventional procedures, trauma, pacemaker

implantation, respiratory, skeleton and pediatric procedures.



K002198 Page 20/2

Technological Characteristics:

The FluoroScan Profile is not only similar to the Wuestec C-Quest, it is, in fact, the same identical system (Model # TCA 4 Plus and TCA 4R Plus) manufactured by Technix. The only difference between the two is the OEM distributor's name placed on the system by Technix.

Performance Data:

Results of prototype testing, as well as compliance testing conducted by an independent health physicist on the Profile C-arm Imaging System, indicates conformance to all applicable performance standards promulgated by the FDA for fluoroscopic imaging systems.

Conclusion:

Based on a comparison to other devices determined to be substantially equivalent through the 510(k) premarket notification process and the claim that the Profile device meets the federal performance standard for radiographic/fluoroscopic x-ray systems per 21 CFR 1020.30-1020.32, FluoroScan Imaging Systems, Inc. concludes that the Profile C-arm System is as safe, as effective and performs as well as other legally marketed c-arm devices.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

## OCT 1 7 2000

William J. Engel Manager, Regulatory Affairs FluoroScan Imaging Systems 650B Anthony Trail Northbrook, IL 60062 Re: K002198

FluoroScan Profile FS-9 and FS-9R Model TCA 4 Plus

and TCA 4R Plus Dated: July 18, 2000 Received: July 20, 2000 Regulatory class: II

21 CFR 892.1650/Procode: 90 JAA 21 CFR 892.1720/Procode: 90 IZL

## Dear Mr. Engel:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing, Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4639. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Daniel G. Schultz, M.D.

Captain, USPHS

Acting Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Page	_1_	of	1

510(k) NUMBER (IF KNOWN): <u>K002198</u>
DEVICE NAME:FluoroScan Profile
INDICATIONS FOR USE:
Indication for Use Statement
The TCA 4 Plus and TCA 4R Plus C-Arm Systems are designed to provide
physicians with fluoroscopic and spot exposures for visualization of
a patient including, but not limited to, general surgical procedures,
orthopedic, critical and emergency care, limited interventional
procedures, trauma, pacemaker implantation, respiratory, skeleton and
pediatric procedures.
09/22/00 William J. Engel
Date William J. Engel/
Manager, Regulatory Affairs
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED.)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use VOR Over-The-Counter-Use (Per 21 CFR 801.109) OR (Optional Format 1-2-96)

(Division Sign-Off)
Division of Reproductive, Abdominal, ENT, and Radiological Devices